Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NSTR: Final Liquidation. Shares cancelled. Deletion time 8:52:56
http://www.otcbb.com/asp/dailylist_detail.asp?d=08/21/2012&mkt_ctg=NON-OTCBB
continues with the massive accumulation of 0075 ... and are being exchanged about 1.5 MM shares at the ask price ... that is very thin ... graphically and technically not be surprised to see me leave a shot like a rocket in NSTR any time ... there is nothing more to add ... who wants to sell insurance venda 0.075 ... to buy ... that is the accumulation is very clear ... I never saw it more clear ... we to be very lucky if one day reaching 1-1.5 dollars ....
what do u mean exactly? thanks
sssssssssslapiiiiiiiiiiinnnnng...theese ask...IS AN ORDER!!!!!!!
is easy...they pay 2 dolars before inside at pink...now the price of NSTR IS 0.08 aprox...
DId NSTR pay 2 bucks per share? If yes, why should one buy NSTR NOW??
0.10 is necesary today...soon better...weeee
NSTR...come back to NASDAQ in a few weeks....i hope so....bid necesary will be 1$
uptick...tic toc...uptick....tic toc...uptick...tic toc...
and I think it will go up to $ 1-1.5 range ... Technology ... NST is a pioneer in the world and although the company is not financially well ... we must remember that until a few weeks was a firm on NASDAQ, we can not forget ... it's impossible not return a reasonable price in a very short time ... well sort of travel friends ... soon we will fly like a rocket ... so many want to buy shares NST ... of A 1 or $ 2 !!!!!!!!!!!
... I have confidence in financial markets since 1990 ... I've ruined 3 times ... ... and I have recovered since the last time I promised to be a predator and win at any cost .... I 35000 ... shares of NSTR in the last 15 operations have earned more than $ 18,000 ... and NSTR will be another in which we will earn good money ...
we need close above 0.09...then tomorrow gap is sure...
ANYBODY IS BUYING AT 0.075 550000 SHARES IN LAST TWO DAYS GUYS....SLAP THE ASK...IS A ONLY WAY...SLAP THE ASK....
NSTR....new videos in board...next week we could explode at 0.5-1$ range...no dificult...the last friday anybody bought 350000 shares at 0.075...anybody knows anything.....may be a sell patent..i heart the same...
APSN...will buy our patent...for 1MM$
NSTR...JO JO JO....let's goooooo baby....and if you drop more...we buy much more.....yeeeeeeeeee
double minimun at o.o5 after days ago..now touch 0.08 great moving..go up baby....we will rich...
if someone lit the fuse can go quietly to $ 1
0.08 IS HERE...LOW LOW FLOAT...IF ANYBODY NEED MAKE MONEY....TO BUY THIS SHARE AND...RICH IN A FEW WEEKS...IS ONLY MY OPINION...
we go to another gap today...but we break to max of 0.12...go up baby...the float is extreme...
we go up at 0.20 in this week...grafic is beautiful...
Yesterday we saw a huge gap opened indicating that there is pressure to buy ... in the course of the meeting was closed off with +45% ... ... ... this bodes
NSTR....EXPLODING SOON VERY SOON...PASSENGERS TO TRAIN...LAST CALL ..
As previously disclosed, on June 12, 2009 Northstar Neuroscience, Inc. (the “Company”) filed Articles of Dissolution (the “Articles of Dissolution”) with the Secretary of State of the State of Washington in accordance with the Company’s Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”). The Articles of Dissolution became effective, and the Company became a dissolved corporation under Washington law, on July 2, 2009 (the “Effective Date”) at 5:00 p.m. Pacific Time.
In addition, the Company’s common stock (the “Common Stock”) was officially delisted from the NASDAQ Global Market at the opening of trading on the Effective Date, pursuant to the previously filed Form 25, which the Company filed with the Securities and Exchange Commission and The NASDAQ Stock Market, Inc. on June 22, 2009. The Company has instructed its transfer agent to close the Company’s stock transfer records as of the close of business on the Effective Date and no longer to recognize or record any transfers of shares of the Common Stock after such date except by will, intestate succession or operation of law.
On July 13, 2009, pursuant to the Plan of Dissolution, the board of directors of the Company approved an initial liquidating distribution of $2.06 per share to the shareholders of record of the Common Stock as of the Effective Date. The Company expects to pay this initial liquidating distribution in cash on or about July 15, 2009.
Pursuant to the requirements of Washington law, the Company intends to retain certain of the remaining assets of the Company to satisfy and make reasonable provision for the satisfaction of any current, contingent or conditional claims and liabilities of the Company until such time as the Company’s board of directors determines that it is appropriate to distribute some or all of such remaining assets. The amount and timing of any subsequent and final distributions will be at the discretion of the Company’s board of directors.
Hey Dante .... I have not much information either..i bought Thursday and Friday added to sell at $ 1-1.5 ... my purchase is on the technical analysis ...
But if NSTR is BK and they paid 2$ to shareholders last week, i suppose the deal is done??
I can't find a lot of info on NSTR. I know they sold their assets.
Do you have more info?
sorry..support at 0.05
i agree...NSTR... no dead...support at 0.06...double touch in two days....may be explode next week...and...the float is very low...NSTR is a candidate to up 1000-2000% in a day...
Anyone who's been long should expect $2.06/cash to hit their account next week.
PERIOD ENDING 31-Mar-09 31-Dec-08 30-Sep-08 30-Jun-08
Net Income (8,898) (4,767) (4,342) (4,124)
Operating Activities, Cash Flows Provided By or Used In
Depreciation (158) (107) (24) (128)
Adjustments To Net Income 2,537 1,783 9 542
Changes In Accounts Receivables - - - -
Changes In Liabilities (752) (1,247) 1,114 (324)
Changes In Inventories - - - -
Changes In Other Operating Activities 331 236 (396) 140
Total Cash Flow From Operating Activities (6,940) (4,102) (3,639) (3,894)
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures - 37 (22) (46)
Investments 21,555 5,076 (6,354) 11,303
Other Cashflows from Investing Activities - - - -
Total Cash Flows From Investing Activities 21,555 5,113 (6,376) 11,257
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid - - - -
Sale Purchase of Stock 435 3 28 42
Net Borrowings - - - -
Other Cash Flows from Financing Activities - - - -
Total Cash Flows From Financing Activities 435 3 28 42
Effect Of Exchange Rate Changes - - - -
Change In Cash and Cash Equivalents $15,050 $1,014 ($9,987) $7,405
bk...but i think NSTR could go up hard in a few days...i think so Dante....
What happened? From 2$ to .08 ?
we go up today like a torpedo...guys....the train goooooo
Dropping the NSTR iBOX with the stock now in play. If it doesn't go for a higher price than what is on the table, you have to revalue many of the biotech's trading below their cash levels. It is called a "bear market"!
9:00AM Northstar Neuroscience: Tang Capital Partners announced that it has made a proposal to acquire NSTR for $2.25 per share in cash (NSTR) 1.50 : Tang Capital Partners announced that it has made a proposal to acquire NSTR in a negotiated transaction for a price of $2.25 per share in cash. The text of the letter sent to the Northstar Board of Directors making such proposal follows. "As a follow-up to recent discussions with management of Northstar Neuroscience, I am writing this letter to set forth a proposal by Tang Capital Partners, LP to acquire Northstar in a negotiated transaction between Tang and Northstar. This is not a proposal to acquire the stock of Northstar directly from the shareholders in a tender offer. To date, we have had access only to Northstar's publicly available information. Based on that information, we are proposing to acquire Northstar for $2.25 per share in cash... This non-binding proposal is contingent on our receipt of a positive response on or before July 9, 2008 and Northstar entering into a binding definitive merger agreement on or before July 23, 2008... We expect the Board to consider our proposal seriously and expeditiously. We are, of course, available to meet with the Board and management at any time and immediately begin negotiations of a definitive agreement."
Northstar Neuroscience Announces Presentation of Long-Term Data of Cortical Stimulation for Depression and Stroke Recovery
Tuesday June 3, 10:00 am ET
Data from PROSPECT and EVEREST Studies Presented at ASSFN Meeting
SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR - News), a developer of medical devices for the treatment of neurological diseases and disorders, announced that long-term data for both the PROSPECT feasibility study of cortical stimulation for depression and the EVEREST pivotal trial studying cortical stimulation for arm/hand disability post stroke were presented this week at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) meeting in Vancouver, British Columbia.
Results of cortical stimulation for the treatment of major depressive disorder were presented on behalf of the PROSPECT investigators by Brian Kopell, M.D. of the Medical College of Wisconsin and Northstar's Vice President of Medical Affairs. PROSPECT is a multi-center, randomized, single-blind study being conducted at Massachusetts General Hospital, the University of Pittsburgh, and the Medical College of Wisconsin.
Dr. Kopell reported that the beneficial effects of cortical stimulation appear to increase over time. With current patient follow-up averaging 52 weeks, improvements on the Hamilton Depression Rating Scale (HDRS) increased from an average of 21 percent at week eight to 32 percent at the most recent follow-up. Over the same period, improvements on the Montgomery-Asberg Depression Rating Scale (MADRS) increased from 22 to 33 percent and the Global Assessment of Functioning (GAF) from 25 to 51 percent. Additionally, four of 11 patients have achieved a response of greater than 50 percent on the HDRS; one additional patient has improved 49 percent. Dr. Kopell noted that the PROSPECT patient cohort represented a very treatment-resistant group, having failed on average more than nine previous therapies.
Dr. Kopell also presented data indicating a statistically significant correlation between electrode location and depression score improvement that Northstar and its clinical collaborators intend to further explore in a study later this year.
Presenting on behalf of the EVEREST study investigators, Robert Levy, M.D., of Northwestern University reported data on cortical stimulation for the recovery of hand/arm function following stroke through 12 and 24 weeks following therapy. The data once again confirms the safety profile of cortical stimulation and suggests that rehabilitation for chronic stroke patients can make a difference. As reported earlier, the EVEREST success criteria at the four-week primary endpoint was not achieved, and analysis of the data set through the 24 week follow up period indicates the overall treatment effect also did not reach statistical significance. However, specifically at the 24 week time-point, there was a statistically significant improvement in the Arm Motor Ability Test (AMAT), one of the study's key outcome measures for activities of daily living, for the treatment group compared to control.
Additionally, Dr. Levy presented follow-up data on the previously reported "evoked movement" subset of cortical stimulation patients who achieved statistically significant improvements compared to control patients at the four week follow up. Through 24 weeks, these patients retained statistically significant benefits compared to the control group.
“The long-term data from PROSPECT and EVEREST further confirms the safety profile of the Renova™ Cortical Stimulation System* and continues to provide researchers new insight into the potential of cortical stimulation for depression and stroke motor recovery,” said John Bowers, Northstar’s President and Chief Executive Officer. “Our team thanks the many clinicians and patients who have participated in these studies. As we've announced, we intend to move forward with a larger study in depression to confirm and build on the results from our PROSPECT study, and we also continue to investigate the potential for cortical stimulation for stroke recovery.
Northstar Neuroscience Inc Q1 2008 Earnings Conference Call Transcript:
http://seekingalpha.com/article/73947-northstar-neuroscience-inc-q1-2008-earnings-conference-call-transcript?source=yahoo
Northstar Neuroscience, Inc. Reports Financial Results for the First Quarter of 2008
Thursday April 24, 4:00 pm ET
SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc., (NASDAQ:NSTR - News), a medical device company developing therapies for the treatment of neurological diseases and disorders, today announced financial results for its first quarter ended March 31, 2008. Investments in the Company’s clinical programs resulted in a net loss of $5.4 million, or $0.21 per share, for the first quarter of 2008, compared to a net loss for the first quarter of the prior year of $6.6 million, or $0.26 per share. Northstar also reported cash and investments of $77.9 million at March 31, 2008, compared to $83.5 million at December 31, 2007.
“During the quarter, we performed a strategic review of our cortical stimulation pipeline and resources, and are now moving forward aggressively with our clinical program investigating cortical stimulation for the treatment of depression,” commented John Bowers, the Company’s President and Chief Executive Officer. “If successful, cortical stimulation therapy could provide an important new option for the millions of patients who do not respond to traditional therapies for depression. We are also continuing analysis of our EVEREST trial data set, including ongoing evaluation of the patient subset that achieved significant benefit from our therapy for stroke recovery. We implemented expense reduction measures to preserve resources to execute our plan, and we look forward to achieving and communicating future milestones as we develop our cortical stimulation therapy.”
Research and development expenses totaled $4.0 million for the quarter ended March 31, 2008, compared to $5.6 million for the first quarter of the prior year. The lower current quarter expenses reflect a reduction in clinical trial and related costs due to the completion of EVEREST trial enrollment in 2007, partially offset by higher compensation and other research and development expenses. Current year expenses also include non-recurring costs associated with the Company’s February 2008 reduction in force.
General and administrative expenses totaled $2.4 million for the quarter ended March 31, 2008, compared to $2.3 million for the first quarter of the prior year. The changes reflect increases in compensation and consulting expenses, including costs related to the reduction in force, partially offset by decreases in market development costs.
Conference Call
Northstar Neuroscience will hold a conference call to discuss first quarter operating results today starting at 4:30 p.m. EDT (1:30 p.m. PDT). To listen to the conference call on your telephone, please dial 1-866-203-2528 (US/Canada) or 1-617-213-8847 (International) and use the participant code "52627360" approximately ten minutes prior to the start time. The conference call will be concurrently webcast. The link to the webcast will be available on the Northstar Neuroscience web site at www.northstarneuro.com under the investor relations section and will be archived for 30 days after the call.
Excellent, nice accumulation line over the last month!
Fred
Finally some nice insider action in NSTR:
http://www.form4oracle.com/company?cik=0001351509&ticker=nstr
http://www.nasdaq.com/asp/holdings.asp?mode=&kind=&timeframe=&intraday=&charttype=&splits=&earnings=&movingaverage=&lowerstudy=&comparison=&index=&symbol=NSTR&symbol=NUVO&symbol=ORXE&symbol=KERX&symbol=AVGN&symbol=VICL&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=form4&mkttype=&pathname=&page=insiderform4&selected=NSTR
Northstar Neuroscience Q4 2007 Earnings Call Transcript:
http://seekingalpha.com/article/69265-northstar-neuroscience-q4-2007-earnings-call-transcript?source=yahoo
The lack of movement irritated me. I sold my measly thousand shares and got in FMT @ .42
best of luck all.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
220
|
Created
|
01/22/08
|
Type
|
Free
|
Moderators |
http://www.northstarneuro.com/
http://finance.yahoo.com/q?s=nstr
http://moneycentral.msn.com/ownership?Symbol=NSTR
http://www.form4oracle.com/company?cik=0001351509&ticker=nstr
Northstar Neuroscience, Inc., a medical device company, focuses on the development and commercialization of neurostimulation therapies for various neurological diseases and disorders. The company is developing a cortical stimulation therapy system called Renova that delivers targeted electrical stimulation to the cortex. Its primary product candidate, Renova-ST, is designed to enhance recovery of hand and arm motor function in patients who have suffered a stroke. The company is also conducting a pivotal trial called EVEREST to evaluate the safety and efficacy of its Renova-ST in conjunction with intensive rehabilitative therapy, in improving hand and arm function in ischemic stroke survivors with chronic upper-extremity hemiparesis. In addition, Northstar Neuroscience is conducting ongoing clinical trials using its proprietary Renova cortical stimulation system for the treatment of various indications, including stroke motor recovery, stroke-related aphasia, tinnitus, and major depressive disorder. The company was founded in 1999. It was formerly known as Vertis Neuroscience, Inc. and changed its name to Northstar Neuroscience, Inc. in 2003. Northstar Neuroscience is headquartered in Seattle, Washington.
Northstar Neuroscience is a medical device company focused on developing and commercializing innovative neuromodulation therapies to restore function and quality of life for people suffering from neurological diseases and disorders.
Northstar Neuroscience has developed the proprietary Renova™ Cortical Stimulation System* that delivers targeted electrical stimulation to the outer layer of the brain - the cerebral cortex. The cortex controls or influences many important neurological functions. Because the outer layer of the brain is more easily accessed than deep brain structures, the required surgery is less invasive.
Northstar’s Renova™ Cortical Stimulation System* is designed to deliver targeted stimulation to the cerebral cortex. The cerebral cortex is the outer layer of the brain and plays a central role in many complex brain functions including movement, behavior, perceptual awareness, language, vision and hearing. Evidence suggests that targeted stimulation of certain areas of the left dorsolateral prefrontal cortex—an area involved with reasoning and emotion—may help treat major depressive disorder.
Cortical stimulation involves a neurosurgical procedure to place an electrode over the brain’s cortex. The electrode is then connected via a lead wire to a neurostimulator implanted in the patient's chest. The pacemaker-sized neurostimulator and lead wire are implanted under the skin. The device is permanently implanted and can deliver continuousstimulation to the brain which is not felt by the patient. Theraputic stimulation is controlled by a clinician using Northstar’s programming system.
The Renova™ System consists of a neurostimulator, cortical stimulation lead and a programming system.
NORTHSTAR NEUROSCIENCE 10AM - FRIDAY - APRIL 17 Preview 8-4 Thursday, April 16 2401 4th Avenue, Suite 300, Seattle, WA | ||||||||||||||||||||||||||
Click small pics to enlarge | ||||||||||||||||||||||||||
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |